only because you asked. the "legacy issues" left to new management were not issues that could be quickly resolved. we had the "Brogdon distraction" for the Street to digest, and many investors - including institutions that could have propped up a stock they believe in may have found it surprising that the company was in such disarray, with late filings, restated financials, earnings disappointments and mounting debt - combined, these things do not present a pretty picture & likely scared many away forever. Yet, with all that's occurred, I truly believe ADK is on sound footing of late, and that management has our interests in mind as they improve performance. just a severe disappointment to me, as I was (guess still am a little) confident it's a good long-term portfolio flip, though it may still be with maybe a shorter horizon now with the conversion to a RE play. just my two.
we see continued upward movement today, "BAGAS"? maybe news from SF & Co.??? one thing's for sure: KTEAM2 is on loose footing, with the other foot in his mouth...after predicting "53 CENTS LOCKED" months ago...
the absence of communication to shareholders of what's happening - or not happening - at VVUS has been obvious, even for the rose-colored glasses crowd. I, too, appreciated the spike yesterday pm, as KTEAM2 will likely be either 1) rather quiet today, toiling in his dungeon of missed predictions/expectations; or, 2) louder than ever, seeking to hog the board by boasting of "BK", "DISCOUNT HAIRCUTS" and "POOR BAGAS"...I believe we'll hear positive news soon, and the $1 accumulations by some will be rewarded. but, one never knows unless you're a fly on the boardroom wall.
thought so...and, then...yes, we've arrived at $1 & change. I feel the winds of change once again, but am uncertain as to what they bring this go round. hopefully, it's a much more attentive and diligent bunch who will look after us lowly shareholders with prudence. or, maybe wishful thinking...
they mentioned "end of first quarter", but nothing...company leadership's credibility is at risk?
imo, it's somewhat ironic that the "change agents" were so critical of the then-current Board...especially the part about the decline in value...
We believe strongly that the Company needs a commercial partner for Qsymia to address the large market for an obesity therapeutic. We believe there is no historical precedent for a small company successfully launching a drug into the primary care physician market. The consequences of the Company's current directors presiding over (i) the failure to secure the proper partnership; (ii) the failure to successfully execute their own commercial launch; and (iii) the failure to gain European regulatory approval, have been quite severe for the Company’s stockholders:
• The Company lost approximately 61.7% of its value from the time of FDA approval in July 2012 to March 7, 2013, the date on which First Manhattan delivered a notice (the "Notice") to the Company indicating its intent to present a proposal and nominate six candidates to stand for election to the Board at the Annual Meeting.1
• In the first six months of launch, Q4 2012 and Q1 2013, the Company generated approximately $6 million in revenue while spending $95 million in operating expenses.
• EU approval provides ten years of exclusivity and therefore, Qsymia approval in the EU would have significant value.
The current Board failed to prepare itself and the management team for the transition from a drug development organization to a highly experienced commercial organization. In our view, this transition must happen now and any delay carries unacceptable risks for the Company and all its stakeholders. As a result, we are seeking to reconstitute the board with independent professionals with the necessary expertise to lead the Company in making this transition in time to take advantage of the opportunity represented by the Company's primary product.
so much for "53 CENTS BAGAS"!!!!!! LOLOLOLOL
the only thing that has been announced thus far by the company, to my knowledge, is the "intent" to return the marketing rights. if something changes, seems an announcement would not only be desirable, but also necessary. but, that's me...
not sure they had the $ to market Stendra effectively...
notice the word "urology"...kteam2, you may be wrong again...(Reuters) - Speciality pharmaceutical company
Endo International Plc (ENDP.O) has held discussions with private equity firms about potential asset sales as it seeks to reduce its more than $8 billion debt pile, according to people familiar with the matter.
The move underscores the challenges facing the Dublin-based company, which has seen its shares drop 77 percent this year amid investor concerns that downward pressure on drug prices could upend its acquisition-driven business model.
Endo, which has a market capitalization of $3 billion, has been exploring several options, including an asset swap with another company, one of the people said. The discussions are at an early stage and no transaction may occur, the people cautioned.
The sources asked not to be identified because the deliberations are confidential. Endo declined to comment.
Endo offers a suite of speciality, generic and over-the-counter medical products spanning therapeutic areas including pain, urology and endocrinology.
The company cut its 2016 earnings guidance in May, fuelling concerns about mounting pressure on its drug prices from payers and regulators.
kteam2 here again to "enlighten" the masses & save them from disaster..."CRUSH BAGAS"!??!!? what, like yesterday, MORON?!!?!?!?